Promising investigational therapeutic monoclonal antibody to treat chronic hepatitis B and D infections medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics
Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax s SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.
Centi-B9 has been engineered to broadly neutralize the mutated emerging coronavirus variants, with demonstrated broad-spectrum reactivity against 99.5% of all coronavirus variants in the U.S.A, and over 98% of coronavirus variants globally, including critical mutations found in the UK B.1.1.7, South African B.1.351, Brazilian P.1, New York B.1.526 and California B.1.429 strains.
/PRNewswire/ Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I.